HER2-positive subtypes of the primary tumor in breast cancer often have heterogeneous metastases, whereas the triple-negative subtype of the tumor remains stable when metastasized
K.V. Konyshev¹,², S.V. Sazonov¹,²
¹Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation;
²Ural State Medical University, Yekaterinburg, Russian Federation
Abstract. Objective: to evaluate the stability of the biological subtype of breast cancer (BC) in regional metastasis in cases with triple negative, hormone-receptor-negative Her2-positive and hormone-receptor-positive Her2-positive subtypes of the primary tumor (PT). Methods. The study was realized on the surgical samples of the primary tumor and regional metastases of 36 patients with breast cancer. An immunohistochemistry (antibodies to estrogen receptors, progesterone receptors, Her2/neu, Ki67) and a silver-enhanced in situ hybridization (SISH) (DNA tags for the HER2 and CEN17 genes) were used to determine the status of the corresponding biomarkers in PT and metastases, followed by assigning the tissue to one of the surrogate biological subtypes of breast cancer. The frequency of changes in the BC subtype in regional metastasis was evaluated, and the detected frequencies were compared using the exact Fischer test. Results and conclusions. The biological subtype of breast cancer with regional metastasis in most cases remains stable among the cases of the entire sample. Discordance of the subtype is most often observed in cases with the hormone-receptor-negative Her2-positive subtype of the primary tumor.
Keywords: breast cancer, metastasis, tumor heterogeneity
There is no conflict of interest.
Contact details of the corresponding author:
Konstantin V. Konyshev
kon-konyshev@yandex.ru
Received 26.11.2020г
For citation:
Konyshev K.V., Sazonov S.V. HER2-positive subtypes of the primary tumor in breast cancer often have heterogeneous metastases, whereas the triple-negative subtype of the tumor remains stable when metastasized. http://vestnikural.ru/article/1150 [Online] Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2020, Vol. 17, no. 4, pp. 285–289. DOI: 10.22138/2500-0918-2020-17-4-285-289 (In Russ)
REFERENCES
1. Zardavas D., Irrthum A., Swanton C., Piccart M. Clinical management of breast cancer heterogeneity. Nat. Rev. Clin. Oncol. 2015; 12 (7): 381–394. DOI: 10.1038/nrclinonc.2015.73
2. Konyshev K.V., Sazonov S.V. Study of Her2/neu status of locoregionally metastasizing breast cancer cells in the cases with equivocal (2+) level of Her2/neu oncoprotein expression in primary tumor tissue [Issledovanie Her2/neu-statusa kletok raka molochnoj zhelezy pri regionarnom metastazirovanii v sluchajah s neopredelennym (2+) urovnem jekspressii Her2/neu v tkani pervichnoj opuholi]. Journal of Ural Medical Academic Science [Vestnik ural’skoi meditsinskoi akademicheskoi nauki]. 2018; 15 (1): 48-54. DOI: 10.22138/2500-0918-2018-15-1-48-54 (in Russ)
3. Konyshev K.V., Sazonov S.V. Changes of immunohistochemical markers in local metastasis of breast cancer [Izmenenie jekspressii immunogistohimicheskih markerov v regionarnyh metastazah raka molochnoj zhelezy]. Archive of Pathology [Arkhiv Patologii]. 2020; 82 (4): 19-26. DOI: 10.17116/patol20208204119 (in Russ)
4. Aitken S.J., Thomas J.S., Langdon S.P., Harrison D.J., Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann. Oncol. 2010; 21 (6): 1254–1261. DOI: 10.1093/annonc/mdp427
5. Konyshev K.V., Brilliant A.A., Sazonov S.V. Ki67 and estrogen receptor changes in breast cancer local metastases. Virchows Archiv. 2016; 469 (S1): 61
6. Konyshev K.V., Brilliant A.A., Sazonov S.V. Change of estrogen receptor expression in breast cancer cells in locoregional metastases [Izmenenie jekspressii receptorov k jestrogenu kletkami karcinomy molochnoj zhelezy pri regionarnom metastazirovanii]. Journal of Ural Medical Academic Science [Vestnik ural’skoi meditsinskoi akademicheskoi nauki]. 2015; 53 (2): 4-6. (in Russ)
7. Amir E., Miller N., Geddie W., Freedman O., Kassam F., Simmons C. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 2012; 30 (6): 587–592. DOI: 10.1200/JCO.2010.33.5232
8. Wolff A.C., Hammond M.E.H., Hicks D.G., Dowsett M., McShane L.M. et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch. Pathol. Lab. Med. 2014; 138 (2): 241–256. DOI: 10.5858/arpa.2013-0953-SA
9. Sazonov S.V., Konyshev K.V. Her2/neu in local metastases and primary focus of breast cancer. Virchows Archiv. 2015; 467 (S1): S55.
10. Konyshev K.V., Brilliant A.A., Sazonov S.V., Leontiev S.L. Her2/neu-status of the primary tumor and locoregional metastases in breast cancer [Her2/neu-status pervichnoj opuholi i regionarnyh metastazov pri rake molochnoj zhelezy]. Journal of Ural Medical Academic Science [Vestnik ural’skoi meditsinskoi akademicheskoi nauki]. 2015; 54 (3): 40-42. (in Russ)
11. Allred D.C., Harvey J.M., Berardo M., Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998; 11 (2): 155–68.
12. Petri A., Sebin K. Medical statistics at a glance. Moscow: GEOTAR-Media; 2015. (in Russ)
Authors
Konstantin V. Konyshev
Institute of Medical Cell Technologies
Cand. Sci. (Med.), pathologist
76a, Vilonov str., Yekaterinburg, Russian Federation, 620137
Ural State Medical University
Reseracher
3 Repin St., Yekaterinburg, Russian Federation, 620028
kon-konyshev@yandex.ru
Sergey V. Sazonov
Institute of Medical Cell Technologies
MD, Dr. Sci. (Med.), Professor, Head of Pathology Department
76a, Vilonov str., Yekaterinburg, Russian Federation, 620137
Ural State Medical University
Head of Department of Histology, Cytology and Embryology
3 Repin St., Yekaterinburg, Russian Federation, 620028
imct@celltechnologies.ru